Edition:
United States

ImmunoGen Inc (IMGN.O)

IMGN.O on Nasdaq

4.72USD
26 May 2017
Change (% chg)

$-0.35 (-6.90%)
Prev Close
$5.07
Open
$5.05
Day's High
$5.05
Day's Low
$4.55
Volume
2,413,289
Avg. Vol
2,060,312
52-wk High
$6.21
52-wk Low
$1.51

IMGN.O

Chart for IMGN.O

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target... (more)

Overall

Beta: 2.61
Market Cap(Mil.): $421.72
Shares Outstanding(Mil.): 89.35
Dividend: --
Yield (%): --

Financials

  IMGN.O Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -1.63 -- --
ROI: -93.07 -8.48 -5.42
ROE: -- -11.31 -4.68

ImmunoGen drug moving ahead in single-agent, combination trials

Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

ImmunoGen drug moving ahead in single-agent, combination trials

May 17 Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

BRIEF-Immunogen reports Q1 loss per share of $0.20

* Immunogen reports recent progress and first quarter 2017 operating results

May 05 2017

BRIEF-Highbridge Capital Management reports 5.34 pct passive stake in Immunogen

* Highbridge Capital Management Reports 5.34 pct passive stake in Immunogen Inc as of April 13 Source text: (http://bit.ly/2opbbaB) Further company coverage:

Apr 24 2017

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 24 2017

BRIEF-Immunogen files for mixed shelf of up to $200 mln – SEC filing

* Immunogen Inc files for mixed shelf of up to $200 million – sec filing Source text for Eikon: Further company coverage:

Mar 03 2017

BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln

* Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016

Feb 17 2017

BRIEF-ImmunoGen announces first patient dosed in phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer

* ImmunoGen announces first patient dosed in forward I Phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer Source text for Eikon: Further company coverage:

Jan 26 2017

BRIEF-Immunogen announces departure of Sandra Poole

* Poole, executive vice president, technical operations and commercial development, will leave company at end of January Source text for Eikon: Further company coverage:

Jan 23 2017

BRIEF-Immunogen says cash balance at Dec 31, 2016 was about $160 mln

* On January 11, 2017, company said that its cash balance at December 31, 2016 (unaudited) was approximately $160 million - SEC filing Source text (http://bit.ly/2jI3xFH) Further company coverage:

Jan 12 2017

More From Around the Web

Competitors

Earnings vs. Estimates